CMMB (Chemomab Therapeutics) Current Accrued Expense: $0.30 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMMB Chemomab Therapeutics Ltd CMMB
34 GF Score
Price $1.92
View Full Analysis

What is Chemomab Therapeutics Current Accrued Expense?

Chemomab Therapeutics CMMB -1.04% 34 Current Accrued Expense is $0.30 Mil as of Mar. 2026. GuruFocus rates CMMB with a GF Score™ of 34/100.

Chemomab Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.30 Mil.

Chemomab Therapeutics's quarterly Current Accrued Expense declined from Sep. 2025 ($0.46 Mil) to Dec. 2025 ($0.34 Mil) and declined from Dec. 2025 ($0.34 Mil) to Mar. 2026 ($0.30 Mil).

Chemomab Therapeutics's annual Current Accrued Expense declined from Dec. 2023 ($3.42 Mil) to Dec. 2024 ($1.54 Mil) and declined from Dec. 2024 ($1.54 Mil) to Dec. 2025 ($0.34 Mil).

Chemomab Therapeutics Current Accrued Expense Related Terms

Chemomab Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics Current Accrued Expense Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.56 3.38 3.42 1.54 0.34

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 0.67 0.46 0.34 0.30
CMMB
34GF Score
Chemomab Therapeutics Ltd CMMB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.30 Mil mean?
Chemomab Therapeutics (CMMB) has a Current Accrued Expense of $0.30 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Chemomab Therapeutics and its competitors.
Is Chemomab Therapeutics' Current Accrued Expense too high?
Chemomab Therapeutics' current Current Accrued Expense is $0.30 Mil. Overall, Chemomab Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' Current Accrued Expense compare to TOVX and BIVI?
Chemomab Therapeutics' Current Accrued Expense of $0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Chemomab Therapeutics and its competitors. Chemomab Therapeutics's current Current Accrued Expense is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current Current Accrued Expense of $0.30 Mil. The current Current Accrued Expense is $0.30 Mil. Chemomab Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current Current Accrued Expense is $0.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score

Get the complete analysis for CMMB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.92
Price